To Study the Prevalence of Extended-Spectrum β-lactamases (ESBL) Producing Uropathogenic Escherichia coli (UPEC) and its Antibiotic Sensitivity Pattern around the Semi-urban Region of Gurugram
Keywords:
ESBL, Urinary tract Infections, E.coli, Antibiotic resistance, Hicrome agar, Double Disk Synergy TestAbstract
Background: The increasing prevalence of E.coli causing UTIs and its resistance pattern has become a major global healthcare concern. ESBL-producing strains, in particular, pose a significant threat to public health and have complicated treatment approaches. Most reports on this issue are from urban areas, so there is a lack of data on antibiotic sensitivity patterns in semi-urban areas.
Aim and Objective: To Study the prevalence of extended-spectrum β-lactamases (ESBL) producing uropathogenic Escherichia coli (UPEC) and its antibiotic sensitivity pattern around the semi-urban region of Gurugram.
Material & Method: Urine samples were processed using the conventional method. As per the CLSI guidelines, confirmed E.coli isolates were tested for antibiotic resistance using the Kirby-Bauer disc diffusion method. All E.coli isolates were subjected to ESBL HiCrome agar and DDST using combination drugs as per the CLSI guidelines for the phenotypic detection.
Results: Out of 485 samples, 256 (52.78%) ESBL E.coli were observed. The antibiogram of the ESBL-producing isolates showed higher resistance rates to cephalosporins compared to non-cephalosporin antibiotics. There was a low degree of resistance observed against aminoglycosides and carbapenem.
Downloads
Metrics
References
Núñez-Samudio, V.; Pecchio, M.; Pimentel-Peralta, G.; Quintero, Y.; Herrera, M.; Landires, I. Molecular Epidemiology of Escherichia coli Clinical Isolates from Central Panama. Antibiotics 2021; 10, 899.
Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014; 28:1–13.
O’Brien VP, Hannan TJ, Nielsen HV, Hultgren SJ. Drug and vaccine development for the treatment and prevention of urinary tract infections. Microbiology spectrum. 2016;4(1):1-4.
Kant S, Misra P, Gupta S, Goswami K, Krishnan A, Nongkynrih B et al. The ballabgarh health and demographic surveillance system (CRHSP-AIMS). Int J Epidemiol. 2018; 42: 758-68
Saltoglu N, Ergonul O, Tulek N, Yemisen M, KadanaliA,KaragozG.Influence of multidrug resistant organisms on the outcome of diabetic foot infection. International Journal of Infectious Diseases.2018; 70:10–4.
Devi LS, Grover SS, Khare S, Broor S, Chattopadhya D. Carbapenemase and NDM 1 production by Escherichia coli and Klebsiellapneumoniae from patients belonging to a rural community in North India hospitalized with community acquired infections. J Commun Dis 2018;50:5 10.
Friedman ND, Kaye KS, Stout JE et al. Health care associated bloodstream infections in adults: A reason to change the accepted definition of community acquired infections. Ann Intern Med 2002;137:791 8.
Clinical Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty Eighth Informational Supplement. M100 S27. Wayne, Pennsylvania, USA: Clinical Laboratory Standard Institute; 2020.
Shaikh S, Fatima J, Shakil S, Rizvi SM, Kamal MA. Antibiotic resistance and extended spectrum beta lactamases: Types, epidemiology and treatment. Saudi J BiolSci 2015;22:90 101
Dash S, Sahu SK, Paty BP. Phenotypic detection of ESBL-producing Enterobacteriaceae using combined disk diffusion, ESBL HiCrome agar, and E-test: A comparative study. J NTR Univ Health Sci 2022;11:200-7
Mohapatra S, Panigrahy R, Tak V et al. Prevalence and resistance pattern of uropathogens from community settings of different regions: an experience from India. Access Microbiol. 2022 Feb 9;4(2):000321. doi: 10.1099/acmi.0.000321. PMID: 35355869; PMCID: PMC8941965.
Devi LS, Broor S, Rautela RS, Grover SS, Chakravarti A, Chattopadhya D. Increasing prevalence of Escherichia coli and Klebsiellapneumoniae producing CTX-M-type extended-spectrum beta-lactamase, carbapenemase, and NDM-1 in patients from a rural community with community acquired infections: A 3 years study. Int J App Basic Med Res 2020;10:156-63
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 8, August 2018
Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extended spectrum beta lactamase producing gram negative pathogens in community acquired urinary tract infections. An increasing challenge for antimicrobial therapy. Infection 2011;39:333 39:
Zhu FH, Rodado MP, Asmar BI, Salimnia H, Thomas R, AbdelHaq N. Risk factors for community acquired urinary tract infections caused by extended spectrum β lactamase (ESBL) producing Escherichia coli in children: A case control study. Infect Dis (Lond) 2019;51:802 9
Bourjilat F, Bouchrif B, Dersi N, Claude JD, Amarouch H, Timinouni M. Emergence of extended spectrum beta lactamase producing Escherichia coli in community acquired urinary infections in Casablanca, Morocco. J Infect DevCtries 2011;5:850 5.
Fatima S, Muhammad IN, Usman S, Jamil S, Khan MN, Khan SI. Incidence of multidrug resistance and extended spectrum betalactamase expression in community acquired urinary tract infection among different age groups of patients. Indian J Pharmacol 2018;50:69 74.
Rishabh Rajput and SurendraSarsaiya. 2018. Significance of Regional Antibiogram and MDR of ESBL Producing Uropathogens Infecting Non-hospitalized Patients: Gurugram. Int.J.Curr.Microbiol.App.Sci. 7(02): 1114-1126
Kumar N, Chatterjee K, Deka S, et al. (March 11, 2021) Increased Isolation of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli From Community-Onset Urinary Tract Infection Cases in Uttarakhand, India. Cureus 13(3): e13837
Nandagopal B, Sankar S, Sagadevan K, Arumugam H, Jesudason MV, Aswathaman K, et al. Frequency of extended spectrum β lactamase producing urinary isolates of Gram negative bacilli among patients seen in a multispecialty hospital in Vellore district, India. Indian J Med Microbiol 2015;33:282 5.
Nisha KV, Veena SA, Rathika SD, Vijaya SM, Avinash SK. Antimicrobial susceptibility, risk factors and prevalence of blacefotaximase, temoneira, and sulfhydryl variable genes among Escherichia coli in community acquired pediatric urinary tract infection. J Lab Physicians 2017;9:156 62.
Abayneh M, Tesfaw G, Abdissa A. Isolation of extended spectrum β lactamase (ESBL ) producing Escherichia coli and Klebsiellapneumoniae from patients with community onset urinary tract infections in Jimma University specialized hospital, Southwest Ethiopia. Canadian J Infect Dis Med Microbiol 2018. pii: 4846159.
Gautam V, Thakur A, Sharma M, Singh A, Bansal S, Sharma A, et al. Molecular characterization of extended spectrum β lactamases among clinical isolates of Escherichia coli &Klebsiellapneumoniae: A multi centric study from tertiary care hospitals in India. Indian J Med Res 2019;149:208 15.
Prabha R, Easow JM, Swapna M. Phenotypic detection of extended spectrum Beta lactamase producing uropathogens using DDST, PCT,Chrom agar and E test A comparative study. Int J CurrMicrobiol App Sci2016;5:565 77.
Chetana GS, Yadhav KML. Rapid phenotypic detection of ESBL producing Enterobacteriaceae using ESBL hichrome agar and e test: A comparative study. Int J CurrAdv Res 2017;6:4665 8.
Lubna Razaqetal.Extended-spectrum β-lactamase variants in Escherichia coli, Klebsiellapneumoniae and Proteus mirabilis from community- and hospital-acquired urinary tract infections.Gene Reports. 2024; Volume 37: 102065.
Kot, B.; Grużewska, A.; Szweda, P.; Wicha, J.; Parulska, U. Antibiotic Resistance of Uropathogens Isolated from Patients Hospitalized in District Hospital in Central Poland in 2020. Antibiotics .2021; 10, 447.
Kresken, M.; Pfeifer, Y.; Wagenlehner, F.; Werner, G.; Wohlfarth, E.; Study Group ‘Antimicrobial Resistance’ of the Paul Ehrlich Society for Infection Therapy. Resistance to Mecillinam and Nine Other Antibiotics for Oral Use in Escherichia coli Isolated from Urine Specimens of Primary Care Patients in Germany, 2019/20. Antibiotics. 2022; 11, 751.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
